Novacyt (NYZ) AI Stock Analysis

Top Page

Novacyt

(Frankfurt:NYZ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Sustained revenue growthThree consecutive half-years of growth, including 18% year-on-year expansion, indicate improving commercial traction rather than a single-period rebound. Continued growth across regions and business lines can broaden the revenue base and support operating leverage as Novacyt scales.

Negative Factors

Persistent losses and cash burnDeep losses and negative operating and free cash flow show that revenue growth has not yet translated into self-funding operations. Continued cash consumption can constrain investment, increase dependence on financing, and leave execution vulnerable until the cost base and margins improve.

Novacyt (NYZ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 41.41M
Dividend Yield: ―
Average Volume (3M): 22.31K
Price to Earnings (P/E): -0.8
Beta (1Y): 0.12
Revenue Growth: 10.36%
EPS Growth: 29.41%
Country: Germany
Employees: 216
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Novacyt Business Overview & Revenue Model

Company Description

Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercializati...

Novacyt Earnings Call Summary

Earnings Call Date:Sep 29, 2026(Q2-2026)|% Change Since:-18.95%|Next Earnings Date:Jun 21, 2021

Earnings Call SentimentPositive

The call was predominantly positive. Management highlighted 18% year-on-year revenue growth, three consecutive half-years of growth, broad geographic and product expansion, the Southern Cross contribution, the DPYD launch, the five-year Illumina agreement and substantial operating-cost reductions. The principal negatives were the decline in gross margin to 56%, lower RUO sales, continued EBITDA losses, cash consumption and an incomplete restructuring program. Management characterized the cost actions as on plan and said cash burn should materially decline after restructuring.

Positive Updates

Revenue Growth Continued

H1 revenue increased significantly to GBP 11.6 million. Excluding Southern Cross Diagnostics, the underlying business still grew by around 9%. Management also reported 18% year-on-year growth for the period and three consecutive half-years of growth, from GBP 9.6 million in H2 2024 through H1 2026.

Negative Updates

Gross Margin Declined

Gross profit was broadly flat at around GBP 6.4 million, while gross margin declined by around 10 percentage points to 56%. Management attributed the reduction to the lower-margin Southern Cross distributor sales, which caused about 3 percentage points of dilution; a fair-value uplift on Southern Cross opening inventory, which caused another approximately 3 percentage points of dilution; and reduced sales of the over-80%-gross-margin Primerdesign business as a proportion of total revenue. Management expects the stock uplift of around GBP 0.5 million to be fully released in the 2026 financial results and continues to expect long-term gross margin above 60%.

Company Guidance

Management said the GBP 4 million cost restructuring is on track, with most of the benefit expected in 2027; at the end of September, around 60 staff released represented around a GBP 2.7 million annual reduction in costs, while nonlabor savings were identified at between GBP 0.5 million and around GBP 700,000, for at least around GBP 3.2 million to GBP 3.4 million of savings expected to start flowing through certainly from 2027 onwards, if not very, very soon over the next couple of weeks. The total stock uplift amount is estimated at around GBP 0.5 million, with all of this expected to be released in the 2026 financial results, and longer term the business still expects to deliver a gross margin of over 60%; underlying cash burn is expected to be materially lower once all the restructuring activities have been completed, with benefits starting in the 2027 financial results. The Illumina agreement is for a 5-year period, and management expects this to be a long-term partnership.

Novacyt Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NYZ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:ALERS	58Neutral	EUR 258.39M	37.57	3.89%	―	6.28%	204.56%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ALIKO	46Neutral	EUR 22.42M	-5.20	-22.03%	―	37.28%	7.83%
FR:ALMKT	45Neutral	EUR 18.94M	1.53	-157.72%	―	3.38%	―
FR:ALMDT	43Neutral	EUR 180.85M	-3.00	271.64%	―	2.16%	-5.26%

* Healthcare Sector Average

Performance Comparison

DE:NYZ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NYZ	Novacyt S.A.	0.41	-0.02	-4.60%
FR:ALMKT	MAUNA KEA TECHNOLOGIES	0.10	-0.00	-1.02%
FR:ALERS	Eurobio-Scientific SA	26.30	2.15	8.90%
FR:ALDMS	Diagnostic Medical Systems	0.91	-0.41	-30.95%
FR:ALIKO	Ikonisys SA	1.42	-0.04	-2.74%
FR:ALMDT	Median Technologies	3.69	0.79	27.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Novacyt AI Stock Analysis